Analyst Ratings

Upgrades, downgrades, and outlook changes from major analysts.

Coverage of analyst actions including upgrades, downgrades, initiations, and price-target changes. This category tracks how institutional research influences market perception, momentum shifts, and short-term price behavior.

Articles

3,520 total articles

UBS Sticks With Neutral on Crocs as Market Sentiment Skews Bearish

UBS Sticks With Neutral on Crocs as Market Sentiment Skews Bearish

UBS has kept a Neutral recommendation and an $85.00 price target on Crocs (NASDAQ:CROX). The broker highlights mixed signals: the share price has outpaced the S&P 500 in the past three months, yet elevated short interest and a weak crowding score point to persistent investor skepticism. UBS identified a trio of near-term performance milestones that…

Truist Sticks With Buy on Robinhood as Shares Slide 10%

Truist Sticks With Buy on Robinhood as Shares Slide 10%

Truist Securities has reaffirmed a Buy rating on Robinhood Markets with a $155.00 price target even as the stock plunged roughly 10% in a single session. The price objective implies roughly 74% upside from the cited $88.99 level, while third-party InvestingPro data shows the shares trading above Fair Value and carrying a price-to-earnings ratio of …

TD Cowen Raises Revvity Price Target to $124, Keeps Buy Rating

TD Cowen Raises Revvity Price Target to $124, Keeps Buy Rating

TD Cowen has lifted its 12-month price target for Revvity Inc (RVTY) to $124.00 from $120.00 while retaining a Buy rating. The revised target sits about 15% above the stock's current price of $107.94 and represents roughly a 3.3% increase over the firm's prior target. The adjustment accompanies recent analyst upward revisions to earnings and comes …

TD Cowen Holds on DaVita, Sets $133 Target After Strong Q4 Results

TD Cowen Holds on DaVita, Sets $133 Target After Strong Q4 Results

TD Cowen has maintained a Hold rating on DaVita with a price target of $133 following the company's fourth-quarter results. DaVita beat revenue and adjusted EBIT estimates in Q4, benefitted from stronger-than-expected performance in its Integrated Kidney Care segment and set fiscal 2026 EBIT guidance slightly above consensus. A separate Fair Value …

BMO Lifts DXC Technology Target to $17 but Keeps Neutral Rating

BMO Lifts DXC Technology Target to $17 but Keeps Neutral Rating

BMO Capital has raised its price target on DXC Technology to $17 from $15 while retaining a Market Perform rating. The upgrade comes alongside a modest valuation argument from InvestingPro data, which shows a low P/E of 6.51 and suggests the stock may be undervalued versus Fair Value estimates. DXC reported stronger-than-expected Q3 2026 EPS and re…